Drug Profile
Research programme: hexokinase II inhibitors - vTv Therapeutics
Latest Information Update: 28 Apr 2019
Price :
$50
*
At a glance
- Originator TransTech Pharma
- Developer vTv Therapeutics LLC
- Class Antineoplastics; Small molecules
- Mechanism of Action Hexokinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2019 No recent reports of development identified for preclinical development in Cancer in USA
- 15 Mar 2016 Calithera Biosciences has patents pending directed to compositions of matter for hexokinase II inhibitors and therapeutic methods of using the compounds in USA (Calithera Biosciences, 10-K, March 2016)
- 20 Mar 2015 Preclinical trials in Cancer in USA (unspecified route)